LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

LLY

952.3

-2.13%↓

JNJ

221.44

-0.1%↓

ABBV

201.01

-0.81%↓

UNH

372.74

+1.5%↑

AZN

182.67

+0.91%↑

Home・Elenco Azioni・Inmode Ltd

Inmode Ltd

Aperta

SettoreSettore sanitario

14 0.57

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.81

Massimo

14.13

Metriche Chiave
By Trading Economics
Entrata	5.2M 27M
Vendite	11M 104M
P/E Media del settore	10.078 49.8
Margine di Profitto	26.022
Dipendenti	660
EBITDA	5.7M 31M

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+15.89% upside

Dividendi
By Dow Jones
Utili prossimi	29 lug 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-120M 907M
Apertura precedente	13.43
Chiusura precedente	14

Notizie sul Sentiment di mercato

By Acuity

50%

166 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

14.1 / 14.44 Supporto e resistenza

Inmode Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

7 mag 2026, 23:58 UTC

Utili

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 mag 2026, 22:57 UTC

Utili

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 mag 2026, 23:52 UTC

Utili

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 mag 2026, 23:45 UTC

Discorsi di Mercato

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 mag 2026, 23:39 UTC

Discorsi di Mercato

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 mag 2026, 23:28 UTC

Discorsi di Mercato

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 mag 2026, 23:11 UTC

Utili

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 mag 2026, 23:06 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 mag 2026, 23:05 UTC

Utili

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 mag 2026, 23:04 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 mag 2026, 23:03 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 mag 2026, 23:02 UTC

Utili

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 mag 2026, 23:00 UTC

Discorsi di Mercato

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

7 mag 2026, 22:45 UTC

Discorsi di Mercato

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 mag 2026, 22:42 UTC

Utili

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 mag 2026, 22:33 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 mag 2026, 22:32 UTC

Utili

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 mag 2026, 22:31 UTC

Utili

Macquarie: 68% of FY Income From International >MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 mag 2026, 22:30 UTC

Utili

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 mag 2026, 22:29 UTC

Utili

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 mag 2026, 22:28 UTC

Utili

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 mag 2026, 22:27 UTC

Utili

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 mag 2026, 22:26 UTC

Utili

Macquarie to End Share Buyback Extended in November>MQG.AU

7 mag 2026, 22:25 UTC

Utili

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Confronto tra pari

Modifica del prezzo

Inmode Ltd Previsione

Obiettivo di Prezzo

By TipRanks

15.89% in crescita

Previsioni per 12 mesi

Media 15.75 USD 15.89%

Alto 19 USD

Basso 14 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Inmode Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 6 che hanno fornito valutazioni azionarie a Inmode Ltd - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

14.1 / 14.44Supporto e resistenza

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

166 / 347 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.